Drugs / PF-06730512
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03146065 | May 2017 → May 2018 | — | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03448692 | Oct 2018 → Feb 2023 | focal segmental glomerulosclerosis | Pfizer | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06730512 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03146065 ↗ |
| Modality | Protein / enzyme biologic | “PF-06730512, an Fc fusion protein that targets the ROBO2/SLIT2 pathway, in healthy adults.” PMID 34369667 ↗ Aug 2021 |
| Route | Intravenous | “intravenous (IV) infusions” NCT03146065 ↗ |